A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
443
Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
Topical ocular drop of lifitegrast administered for 4 weeks
Topical ocular drop of perfluorohexyloctane administered for 4 weeks
Total corneal fluorescein staining change from baseline
Time frame: Baseline, day 29
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Eye Doctors of Arizona, PLLC
Phoenix, Arizona, United States
Global Research Management, Inc.
Glendale, California, United States
SoCal Eye - Lakewood Clinic
Long Beach, California, United States
LoBue Laser and Eye Medical Center
Murrieta, California, United States
Eye Research Foundation, Inc.
Newport Beach, California, United States
Wolstan and Goldberg Eye Associates
Torrance, California, United States
Segal Drug Trials/Office of Bruce A Segal, MD
Delray Beach, Florida, United States
Bowden Eye and Associates
Jacksonville, Florida, United States
Shettle Eye Research, Inc
Largo, Florida, United States
Clayton Eye Clinical Research, LLC
Morrow, Georgia, United States
...and 22 more locations